Display options
Cite
Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015;3(2):64-76
Armstrong, C. M., & Gao, A. C. (2015). Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. American journal of clinical and experimental urology, 3(2), 64-76.
Armstrong, Cameron M, and Gao, Allen C. "Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies." American journal of clinical and experimental urology vol. 3,2 (2015): 64-76.
Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015 Aug 08;3(2):64-76. eCollection 2015. PMID: 26309896; PMCID: PMC4539108.
Copy Download .nbib Format: NLM
Share it on

Am J Clin Exp Urol. 2015 Aug 08;3(2):64-76. eCollection 2015.

Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

American journal of clinical and experimental urology

Cameron M Armstrong, Allen C Gao

Affiliations

  1. Department of Urology, University of California at Davis Sacramento, CA, USA.
  2. Department of Urology, University of California at Davis Sacramento, CA, USA ; Comprehensive Cancer Center, University of California at Davis Sacramento, CA, USA.

PMID: 26309896 PMCID: PMC4539108

Abstract

Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). At present, the approved chemotherapies for CRPC include systemic drugs (docetaxel and cabazitaxel) and agents that target androgen signaling, including enzalutamide and abiraterone. While up to 30% of patients have primary resistance to these treatments, each of these drugs confers a significant survival benefit for many. Over time, however, all patients inevitably develop resistance to treatment and their disease will continue to progress. Several key mechanisms have been identified that give rise to drug resistance. Expression of constitutively active variants of the androgen receptor, such as AR-V7, intracrine androgens and overexpression of androgen synthesis enzymes like AKR1C3, and increased drug efflux through ABCB1 are just some of the many discovered mechanisms of drug resistance. Treatment strategies are being developed to target these pathways and reintroduce drug sensitivity. Niclosamide has been discovered to reduce AR-V7 activity and synergized to enzalutamide. Indomethacin has been explored to inhibit AKR1C3 activity and showed to be able to reverse resistance to enzalutamide. ABCB1 transport activity can be mitigated by the phytochemical apigenin and by antiandrogens such as bicalutamide, with each improving cellular response to chemotherapeutics. By better understanding the mechanisms by which drug resistance develops improved treatment strategies will be made possible. Herein, we review the existing knowledge of CRPC therapies and resistance mechanisms as well as methods that have been identified which may improve drug sensitivity.

Keywords: Drug resistance; castration resistant; prostate cancer; treatment strategies

References

  1. Nat Med. 2000 Jun;6(6):703-6 - PubMed
  2. J Steroid Biochem Mol Biol. 2000 Dec 1;75(1):1-10 - PubMed
  3. Eur J Cancer. 2002 May;38(8):1090-9 - PubMed
  4. Int J Cancer. 2002 Jul 20;100(3):309-17 - PubMed
  5. Cell Mol Life Sci. 2002 Jul;59(7):1198-211 - PubMed
  6. Cancer Res. 2003 May 1;63(9):2206-15 - PubMed
  7. Clin Cancer Res. 2004 Nov 1;10(21):7220-8 - PubMed
  8. Clin Cancer Res. 2004 Dec 15;10(24):8147-51 - PubMed
  9. Prostate. 2005 Oct 1;65(2):141-50 - PubMed
  10. Oncogene. 2006 Oct 5;25(45):6113-22 - PubMed
  11. Clin Cancer Res. 2006 Sep 15;12(18):5578-86 - PubMed
  12. Clin Adv Hematol Oncol. 2006 Aug;4(8):588-90 - PubMed
  13. J Biol Chem. 2008 Feb 8;283(6):3349-56 - PubMed
  14. Biochim Biophys Acta. 2008 Apr;1785(2):96-132 - PubMed
  15. J Biol Chem. 2008 Jul 25;283(30):20635-44 - PubMed
  16. Cancer Res. 2008 Jul 1;68(13):5469-77 - PubMed
  17. Cancer Res. 2009 Jan 1;69(1):16-22 - PubMed
  18. Nat Clin Pract Urol. 2009 Feb;6(2):76-85 - PubMed
  19. Cancer Res. 2009 Mar 15;69(6):2305-13 - PubMed
  20. Science. 2009 May 8;324(5928):787-90 - PubMed
  21. Prostate. 2009 Oct 1;69(14):1579-85 - PubMed
  22. Clin Cancer Res. 2009 Aug 1;15(15):4815-22 - PubMed
  23. Mol Cancer. 2009 Jul 31;8:57 - PubMed
  24. Br J Cancer. 2009 Sep 15;101(6):951-6 - PubMed
  25. Prostate. 2010 Mar 1;70(4):433-42 - PubMed
  26. Cell Biol Int. 2010 Jan 25;34(2):177-84 - PubMed
  27. Cancer Cell. 2010 Jun 15;17(6):535-46 - PubMed
  28. J Clin Invest. 2010 Aug;120(8):2715-30 - PubMed
  29. Cancer Res. 2010 Oct 15;70(20):7992-8002 - PubMed
  30. Lancet. 2010 Oct 2;376(9747):1147-54 - PubMed
  31. Cancer Res. 2010 Nov 15;70(22):9253-64 - PubMed
  32. Int J Oncol. 2011 Jan;38(1):33-9 - PubMed
  33. Can Urol Assoc J. 2010 Dec;4(6):380-4 - PubMed
  34. Cancer Res. 2011 Mar 15;71(6):2108-17 - PubMed
  35. PLoS One. 2011 Apr 28;6(4):e19059 - PubMed
  36. N Engl J Med. 2011 May 26;364(21):1995-2005 - PubMed
  37. Prostate. 2011 Aug 1;71(11):1158-66 - PubMed
  38. Endocr Relat Cancer. 2011 Sep 20;18(5):R183-96 - PubMed
  39. Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13728-33 - PubMed
  40. Clin Cancer Res. 2011 Sep 15;17(18):5913-25 - PubMed
  41. Cancer Res. 2011 Oct 15;71(20):6503-13 - PubMed
  42. J Biol Chem. 2011 Oct 14;286(41):36152-60 - PubMed
  43. Mol Cancer. 2011 Oct 07;10:126 - PubMed
  44. Mol Cancer Ther. 2012 Feb;11(2):329-39 - PubMed
  45. J Clin Endocrinol Metab. 2012 Feb;97(2):507-16 - PubMed
  46. Biomaterials. 2012 Mar;33(7):2223-9 - PubMed
  47. Mol Cell Endocrinol. 2012 Sep 5;360(1-2):38-43 - PubMed
  48. Biomaterials. 2012 Apr;33(12):3494-501 - PubMed
  49. Neoplasia. 2012 Jan;14(1):74-83 - PubMed
  50. Ann Oncol. 2012 Nov;23(11):2943-7 - PubMed
  51. N Engl J Med. 2012 Sep 27;367(13):1187-97 - PubMed
  52. Prostate. 2013 Mar;73(4):418-27 - PubMed
  53. Prostate. 2013 Apr;73(5):512-21 - PubMed
  54. Clin Cancer Res. 2012 Dec 15;18(24):6574-9 - PubMed
  55. Cancer Res. 2013 Jan 15;73(2):483-9 - PubMed
  56. Prostate. 2013 Jun;73(9):913-22 - PubMed
  57. Br J Cancer. 2013 Mar 19;108(5):1079-91 - PubMed
  58. Eur J Cancer. 2013 Apr;49(6):1374-403 - PubMed
  59. J Urol. 2013 Aug;190(2):429-38 - PubMed
  60. Mol Cancer Ther. 2013 Aug;12(8):1629-37 - PubMed
  61. J Clin Invest. 2013 Jul;123(7):2948-60 - PubMed
  62. Prostate. 2013 Sep;73(12):1336-44 - PubMed
  63. Cancer Discov. 2013 Sep;3(9):1020-9 - PubMed
  64. Cancer Discov. 2013 Sep;3(9):1030-43 - PubMed
  65. Mol Cancer Ther. 2013 Sep;12(9):1829-36 - PubMed
  66. Urol Oncol. 2013 Nov;31(8):1846 - PubMed
  67. Prostate. 2014 Feb;74(2):201-9 - PubMed
  68. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  69. Ann Oncol. 2014 Feb;25(2):429-34 - PubMed
  70. Eur Urol. 2014 Oct;66(4):646-52 - PubMed
  71. Cancer Res. 2014 Apr 15;74(8):2270-2282 - PubMed
  72. Diagn Pathol. 2014 Feb 26;9:42 - PubMed
  73. Endocr Relat Cancer. 2014 May 06;21(3):435-42 - PubMed
  74. Oncogene. 2014 Sep 4;33(36):4521-30 - PubMed
  75. Cancer Lett. 2014 Jun 28;348(1-2):126-34 - PubMed
  76. Clin Cancer Res. 2014 Jun 15;20(12):3198-3210 - PubMed
  77. Eur Urol. 2015 Aug;68(2):228-35 - PubMed
  78. Am Soc Clin Oncol Educ Book. 2014;:117-31 - PubMed
  79. Br J Cancer. 2014 Sep 23;111(7):1249-54 - PubMed
  80. N Engl J Med. 2014 Jul 31;371(5):424-33 - PubMed
  81. Ther Adv Urol. 2014 Jun;6(3):97-104 - PubMed
  82. Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9235-40 - PubMed
  83. Transl Androl Urol. 2013 Sep 1;2(3):137-147 - PubMed
  84. Prostate. 2014 Nov;74(15):1560-8 - PubMed
  85. PLoS One. 2014 Sep 30;9(9):e107991 - PubMed
  86. Oncotarget. 2014 Sep 15;5(17):7217-59 - PubMed
  87. J Natl Cancer Inst Monogr. 2014 Nov;2014(49):255-64 - PubMed
  88. Nat Commun. 2014 Nov 25;5:5548 - PubMed
  89. Mol Oncol. 2014 Nov 15;:null - PubMed
  90. Eur Urol. 2015 Jun;67(6):981-985 - PubMed
  91. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7 - PubMed
  92. Lancet Oncol. 2015 Feb;16(2):152-60 - PubMed
  93. Cancer Res. 2015 Apr 1;75(7):1413-22 - PubMed
  94. Cancer Cell. 2015 Feb 9;27(2):223-39 - PubMed
  95. Clin Cancer Res. 2015 Feb 15;21(4):795-807 - PubMed
  96. Prostate. 2015 Sep;75(13):1341-53 - PubMed
  97. Clin Cancer Res. 2015 Sep 15;21(18):4133-42 - PubMed
  98. Nature. 2015 Jul 16;523(7560):347-51 - PubMed
  99. Mol Cancer Ther. 2015 Aug;14(8):1884-95 - PubMed
  100. Urol Oncol. 2016 Nov;34(11):520 - PubMed
  101. Proc Natl Acad Sci U S A. 1973 Mar;70(3):765-8 - PubMed
  102. Mol Endocrinol. 1993 Dec;7(12):1541-50 - PubMed

Publication Types

Grant support